Advisory Committee; Nonprescription Drugs Advisory Committee; Renewal, 78371-78372 [2023-25100]
Download as PDF
<![CDATA[
78371
Federal Register / Vol. 88, No. 219 / Wednesday, November 15, 2023 / Notices
(4) ways to minimize the burden of
the collection of information on
respondents, including using automated
collection techniques when appropriate,
and other forms of information
technology.
The Administration for Community
Living (ACL) at the Department of
Health and Human Services (HHS) is
requesting a generic clearance for
purposes collecting data with a focus on
the awareness, understanding, attitudes,
preferences, or experiences of customers
or other stakeholders relating to existing
or future services, products, or
communication materials. ACL defines
routine customer feedback as
information that provides useful
insights to improve existing or future
service deliveries, products, or
communication materials. ACL is
requesting approval for customer
surveys with the purpose of the
collecting data to assist the agency in
improving existing or future service
deliveries, products, or communication
materials; responses are voluntary: the
collection does not impose a significant
burden on respondents; the collection
does not employ statistical methods to
have practical utility; and the data
results are not publicly shared.
The types of information collection
activities will include:
1. Customer Comment Card/Complaint
Form
2. Customer Satisfaction Qualitative
Surveys
3. Technical Assistance
4. Usability Testing (e.g., website or
Software)
5. Small Discussion Group
6. Focus Group
7. One-time or panel discussion groups
8. Moderated, un-moderated, in-person,
and/or remote-usability studies
9. Testing of a survey or other collection
to refine questions
10. Post-transaction customer surveys
11. On-line surveys
ACL was created around the
fundamental principle that older adults
and people of all ages with disabilities
should be able to live where they
choose, with the people they choose,
and with the ability to participate fully
in their communities. By funding
services and supports provided
primarily by networks of communitybased organizations, and with
investments in research, education, and
innovation, ACL helps make this
principle a reality for millions of
Americans. Integral to this role, ACL
will use this mechanism to conduct
routine customer feedback for ACL
programs. The proposed data collection
template may be found on the ACL
website for review at: https://
www.acl.gov/about-acl/public-input.
Estimated Program Burden: ACL
estimates the burden of this collection
of information as follows:
The annual burden hours (2,521)
requested, and the anticipated number
of respondents (10,086) are based on the
number of potential customer feedback
respondents. Over the course of a threeyear clearance for this generic
information collection, ACL estimates a
three-year burden drawdown amount of
7,564.5 burden hours and 30,258
respondents.
ESTIMATED ANNUALIZED BURDEN TABLE
Form
ACL Potential Customer or Stakeholder.
ACL Generic Clearance for the Collection of Routine Customer
Feedback.
Dated: November 8, 2023.
Alison Barkoff,
Principal Deputy Administrator for the
Administration for Community Living,
performing the duties of the Administrator
and the Assistant Secretary for Aging.
[FR Doc. 2023–25129 Filed 11–14–23; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0806]
Advisory Committee; Nonprescription
Drugs Advisory Committee; Renewal
AGENCY:
Food and Drug Administration,
HHS.
ddrumheller on DSK120RN23PROD with NOTICES1
Annual
number of
respondents
Type of respondent
Notice; renewal of Federal
advisory committee.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
renewal of the Nonprescription Drugs
Advisory Committee by the
Commissioner of Food and Drugs (the
Commissioner). The Commissioner has
SUMMARY:
VerDate Sep<11>2014
17:49 Nov 14, 2023
Jkt 262001
10,086
determined that it is in the public
interest to renew the Nonprescription
Drugs Advisory Committee for an
additional 2 years beyond the charter
expiration date. The new charter will be
in effect until the August 27, 2025,
expiration date.
DATES: Authority for the
Nonprescription Drugs Advisory
Committee will expire on August 27,
2025, unless the Commissioner formally
determines that renewal is in the public
interest.
FOR FURTHER INFORMATION CONTACT:
Moon Hee Choi, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, NDAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services and by the General Services
Administration, FDA is announcing the
renewal of the Nonprescription Drugs
Advisory Committee (the Committee).
The Committee is a discretionary
Federal advisory committee established
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
Burden hours
per response
.25
Total annual
burden hours
2, 521
to provide advice to the Commissioner.
The Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to helping to ensure safe and
effective drugs for human use and, as
required, any other product for which
FDA has regulatory responsibility.
The Committee reviews and evaluates
available data concerning the safety and
effectiveness of over-the-counter
(nonprescription) human drug products,
or any other FDA-regulated product, for
use in the treatment of a broad spectrum
of human symptoms and diseases and
advises the Commissioner either on the
promulgation of monographs
establishing conditions under which
these drugs are generally recognized as
safe and effective and not misbranded or
on the approval of new drug
applications for such drugs. The
Committee serves as a forum for the
exchange of views regarding the
prescription and nonprescription status,
including switches from one status to
another, of these various drug products
and combinations thereof. The
Committee may also conduct peer
E:\FR\FM\15NON1.SGM
15NON1
78372
Federal Register / Vol. 88, No. 219 / Wednesday, November 15, 2023 / Notices
review of agency sponsored intramural
and extramural scientific biomedical
programs in support of FDA’s mission
and regulatory responsibilities.
The Committee shall consist of 10
voting members including the Chair.
Members and the Chair are selected by
the Commissioner or designee from
among authorities knowledgeable in the
fields of internal medicine, family
practice, clinical toxicology, clinical
pharmacology, pharmacy, dentistry, and
related specialties. Members will be
invited to serve for overlapping terms of
up to 4 years. Non-Federal members of
this committee will serve as Special
Government Employees,
representatives, or Ex-Officio members.
Federal members will serve as Regular
Government Employees, or Ex-Officios.
The core of voting members may
include one technically qualified
member, selected by the Commissioner
or designee, who is identified with
consumer interests and is recommended
by either a consortium of consumeroriented organizations or other
interested persons. In addition to the
voting members, the Committee may
include one non-voting representative
member who is identified with industry
interests. There may also be an alternate
industry representative.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/advisory-committees/
nonprescription-drugs-advisorycommittee/nonprescription-drugsadvisory-committee-charter or by
contacting the Designated Federal
Officer (see FOR FURTHER INFORMATION
CONTACT). In light of the fact that no
change has been made to the Committee
name or description of duties, no
amendment will be made to 21 CFR
14.100.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app.). For general information
related to FDA advisory committees,
please visit us at https://www.fda.gov/
AdvisoryCommittees/default.htm.
ddrumheller on DSK120RN23PROD with NOTICES1
Dated: November 8, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–25100 Filed 11–14–23; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:49 Nov 14, 2023
Jkt 262001
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2021–0830]
National Boating Safety Advisory
Committee; Vacancies
United States Coast Guard,
Department of Homeland Security.
ACTION: Request for applications.
AGENCY:
The U.S. Coast Guard is
accepting applications to fill four
vacancies on the National Boating
Safety Advisory Committee
(Committee). This Committee advises
the Secretary of Homeland Security, via
the Commandant of the U.S. Coast
Guard, on matters relating to national
recreational boating safety.
DATES: Completed applications must
reach the U.S. Coast Guard on or before
December 15, 2023.
ADDRESSES: Applications must include
(a) a cover letter expressing interest in
an appointment to the National Boating
Safety Advisory Committee, (b) a
resume detailing the applicant’s
relevant experience for the position
applied for, and (c) a brief biography.
Applications should be submitted via
email with the subject line ‘‘Application
for NBSAC’’ to Mr. Jeff Decker at
NBSAC@uscg.mil.
FOR FURTHER INFORMATION CONTACT: Mr.
Jeff Decker, Alternate Designated
Federal Officer of the National Boating
Safety Advisory Committee; telephone
574–607–8235 or email at NBSAC@
uscg.mil.
SUPPLEMENTARY INFORMATION: The
National Boating Safety Advisory
Committee is a Federal advisory
committee. The Committee was
established on December 4, 2018, by
section 601 of the Frank LoBiondo Coast
Guard Authorization Act of 2018, Public
Law 115–282, 132 Stat. 4192, and is
codified in 46 U.S.C. 15105. The
Committee must operate under the
provisions of the Federal Advisory
Committee Act, (Pub. L. 117–286, 5
U.S.C., ch. 10), and 46 U.S.C. 15109.
The National Boating Safety Advisory
Committee provides advice, consults
with, and make recommendations to the
Secretary of Homeland Security, via the
Commandant of the U.S. Coast Guard,
on matters relating to national
recreational boating safety.
The Committee is required to meet at
least once a year in accordance with 46
U.S.C. 15109(a). We expect the
Committee will hold meetings at least
twice a year, but it may meet more
frequently. The meetings may be held
SUMMARY:
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
virtually or held at the location across
the country selected by the U.S. Coast
Guard.
All members serve at their own
expense and receive no salary or other
compensation from the Federal
Government. The only compensation
the members may receive is for travel
expenses, including per diem in lieu of
subsistence, and or/actual reasonable
expenses incurred in the performance of
their direct duties for the Committee in
accordance with Federal Travel
Regulations. If you are appointed as a
member of the Committee, you will be
required to sign a Non-Disclosure
Agreement and a Gratuitous Services
Agreement.
Under provisions in 46 U.S.C.
15109(f)(6), if you are appointed as a
member of the Committee, your
membership term will expire on
December 31st of the third full year after
the effective date of your appointment.
Members serve at the pleasure of the
Secretary of Homeland Security and
may be removed prior to the end of their
term for just cause. The Secretary of
Homeland Security may require an
individual to have passed an
appropriate security background
examination before appointment to the
Committee, 46 U.S.C. 15109(f)(4).
In this solicitation for Committee
members, we will consider applications
for four (4) positions:
State official responsible for State
boating safety programs (4 positions).
Each member of the Committee serves
as a representative and must have
particular expertise, knowledge, and
experience in matters relating to the
function of the Committee, which is to
advise the Secretary of Homeland
Security on the matters described above.
The members who will fill the four
positions will be appointed to represent
the positions described above and are
not Special Government Employees as
defined in 18 U.S.C. 202(a).
In order for the Department, to fully
leverage broad-ranging experience and
education, the National Boating Safety
Advisory Committee must be diverse
with regard to professional and
technical expertise. The Department is
committed to pursuing opportunities,
consistent with applicable law, to
compose a committee that reflects the
diversity of the Nation’s people.
If you are interested in applying to
become a member of the Committee,
email your application to NBSAC@
uscg.mil as provided in the ADDRESSES
section of this notice. Applications must
include: (1) a cover letter expressing
interest in an appointment to the
National Boating Safety Advisory
Committee; (2) a resume detailing the
E:\FR\FM\15NON1.SGM
15NON1
]]>Agencies
[Federal Register Volume 88, Number 219 (Wednesday, November 15, 2023)]
[Notices]
[Pages 78371-78372]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25100]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0806]
Advisory Committee; Nonprescription Drugs Advisory Committee;
Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of Federal advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
renewal of the Nonprescription Drugs Advisory Committee by the
Commissioner of Food and Drugs (the Commissioner). The Commissioner has
determined that it is in the public interest to renew the
Nonprescription Drugs Advisory Committee for an additional 2 years
beyond the charter expiration date. The new charter will be in effect
until the August 27, 2025, expiration date.
DATES: Authority for the Nonprescription Drugs Advisory Committee will
expire on August 27, 2025, unless the Commissioner formally determines
that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT: Moon Hee Choi, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, [email protected].
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services and by the General Services
Administration, FDA is announcing the renewal of the Nonprescription
Drugs Advisory Committee (the Committee). The Committee is a
discretionary Federal advisory committee established to provide advice
to the Commissioner. The Committee advises the Commissioner or designee
in discharging responsibilities as they relate to helping to ensure
safe and effective drugs for human use and, as required, any other
product for which FDA has regulatory responsibility.
The Committee reviews and evaluates available data concerning the
safety and effectiveness of over-the-counter (nonprescription) human
drug products, or any other FDA-regulated product, for use in the
treatment of a broad spectrum of human symptoms and diseases and
advises the Commissioner either on the promulgation of monographs
establishing conditions under which these drugs are generally
recognized as safe and effective and not misbranded or on the approval
of new drug applications for such drugs. The Committee serves as a
forum for the exchange of views regarding the prescription and
nonprescription status, including switches from one status to another,
of these various drug products and combinations thereof. The Committee
may also conduct peer
[[Page 78372]]
review of agency sponsored intramural and extramural scientific
biomedical programs in support of FDA's mission and regulatory
responsibilities.
The Committee shall consist of 10 voting members including the
Chair. Members and the Chair are selected by the Commissioner or
designee from among authorities knowledgeable in the fields of internal
medicine, family practice, clinical toxicology, clinical pharmacology,
pharmacy, dentistry, and related specialties. Members will be invited
to serve for overlapping terms of up to 4 years. Non-Federal members of
this committee will serve as Special Government Employees,
representatives, or Ex-Officio members. Federal members will serve as
Regular Government Employees, or Ex-Officios. The core of voting
members may include one technically qualified member, selected by the
Commissioner or designee, who is identified with consumer interests and
is recommended by either a consortium of consumer-oriented
organizations or other interested persons. In addition to the voting
members, the Committee may include one non-voting representative member
who is identified with industry interests. There may also be an
alternate industry representative.
Further information regarding the most recent charter and other
information can be found at https://www.fda.gov/advisory-committees/nonprescription-drugs-advisory-committee/nonprescription-drugs-advisory-committee-charter or by contacting the Designated Federal
Officer (see FOR FURTHER INFORMATION CONTACT). In light of the fact
that no change has been made to the Committee name or description of
duties, no amendment will be made to 21 CFR 14.100.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please visit us at https://www.fda.gov/AdvisoryCommittees/default.htm.
Dated: November 8, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-25100 Filed 11-14-23; 8:45 am]
BILLING CODE 4164-01-P
